The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery
Open accessAbstract
Summary Background: A previous pooled analysis of the STARS/ROSEL trials showed higher survival after stereotactic ablative radiotherapy (SABR) compared to surgery for operable early-stage non-small cell lung cancer (NSCLC), but that analysis had notable limitations. This study reports long-term results of the STARS trial, in which the SABR arm was re-accrued with greater sample size, along with a protocol-specified propensity matched comparison with a prospectively registered, contemporary institutional cohort of patients who underwent video-assisted thoracoscopic surgical lobectomy with mediastinal lymph node dissection (VATS L-MLND). Methods: Patients were ≥18 years of age and Zubrod performance status of 0–2, with newly-diagnosed and histologically confirmed ≤3 cm NSCLC with N0M0 disease (squamous cell, adenocarcinoma, large cell, or NSCLC not otherwise specified). This trial (NCT02357992) completed enrollment and did not include patients from the prior pooled analysis. Operability was defined as candidacy for lobectomy as determined by a thoracic surgeon using several objective criteria. PET/CT was required, and EBUS was strongly recommended for all patients. SABR dosing was 54 Gy in three fractions (for peripheral lesions) or 50 Gy in four fractions (for central tumors; simultaneous integrated boost to gross tumor totaling 60 Gy). The primary endpoint was the 3-year overall survival (OS) rate. Non-inferiority could be claimed if the 3-year OS rate after SABR was lower than that after VATS L-MLND by ≤12% and the upper bound of the 95% confidence interval (CI) of the hazard ratio (HR) was <1.965. Propensity matching consisted of determining a propensity score using a multivariable logistic regression model encompassing several covariates (age, tumor size, histology, performance status, and the interaction of age and sex); based on the propensity scores, one SABR patient was randomly matched with one VATS L-MLND patient using a 5-to-1 digit greedy match algorithm. Findings: Enrollment was from September 1, 2015 and completed on January 31, 2017. The median follow-up time for the 80 SABR patients was 5.1 years (IQR, 3.9 – 5.8 years). SABR was tolerated well, with no grade 4–5 toxicity and one case (1.3%) of grade 3 dyspnea. The OS was 91% (95% CI, 85–98%) at 3 years and 87% (95% CI, 79–95%) at 5 years. The OS in the propensity-matched VATS L-MLND cohort was 91% (95% CI 85%–98%) at 3 years and 84% (95% CI 76%–93%) at 5 years. There were no significant OS differences between groups (HR 0.86, 95%CI 0.45–1.65, p=0.65). Interpretation: Long-term survival after SABR is non-inferior to VATS L-MLND for operable stage IA NSCLC. SABR remains promising for such cases but multidisciplinary management is strongly recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peduzzi, P., Concato, J., Feinstein, A. R., & Holford, T. R. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(95)00048-8 · Cited by 2,154
Chang, J. Y., Senan, S., Paul, M. A., Mehran, R. J., Louie, A. V., Balter, P., Groen, H. J. M., McRae, S. E., Widder, J., Feng, L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70168-3 · Cited by 1,462
Self-citationAustin, P. C., Grootendorst, P., & Anderson, G. M. (2007) · Statistics in Medicine · doi:10.1002/sim.2580 · Cited by 1,137
Balance diagnostics after propensity score matching
written on behalf of AME Big-Data Clinical Trial Collaborative Group, Zhang, Z., Kim, H. J., Lonjon, G., & Zhu, Y. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2018.12.10 · Cited by 1,031
Theelen, W. S. M. E., Chen, D., Verma, V., Hobbs, B. P., Peulen, H. M. U., Aerts, J. G. J. V., Bahce, I., Niemeijer, A. L. N., Chang, J. Y., de Groot, P. M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30391-x · Cited by 564
Self-citationNon–Small Cell Lung Cancer, Version 6.2015
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0071 · Cited by 478
Self-citationNagata, Y., Hiraoka, M., Shibata, T., Onishi, H., Kokubo, M., Karasawa, K., Shioyama, Y., Onimaru, R., Kozuka, T., Kunieda, E., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.07.2278 · Cited by 449
Krall, J. A., Reinhardt, F., Mercury, O. A., Pattabiraman, D. R., Brooks, M. W., Dougan, M., Lambert, A. W., Bierie, B., Ploegh, H. L., Dougan, S. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3464 · Cited by 442
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Bernstein, M. B., Krishnan, S., Hodge, J. W., & Chang, J. Y. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.30 · Cited by 399
Self-citationToward Precision Radiotherapy for Use with Immune Checkpoint Blockers
Vanpouille-Box, C., Formenti, S. C., & Demaria, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0037 · Cited by 171
Cited by
Current and future applications of artificial intelligence in lung cancer and mesothelioma
Roche, J. J., Seyedshahi, F., Rakovic, K., Thu, A. W., Le Quesne, J., & Blyth, K. G. (2025) · Thorax · doi:10.1136/thorax-2024-222054 · Cited by 11
Metadata
- Authors
- Chang, J. Y., Mehran, R. J., Feng, L., Verma, V., Liao, Z., Welsh, J. W., Lin, S. H., O'Reilly, M. S., Jeter, M. D., Balter, P. A., McRae, S. E., Berry, D., Heymach, J. V., Roth, J. A., Antonoff, M., Hofstetter, W., Rajaram, R., Rice, D., Sepesi, B., Swisher, S., Vaporciyan, A., Walsh, G., DeGraaf, C., Correa, A., Chen, A., Gandhi, S., Komaki, R., Lee, P., Nguyen, Q.-N., Ning, M., Gao, S., Pollard-Larkin, J., Nitsch, P., Sadagopan, R., & Wang, X.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2021-10
- Volume
- 22
- Issue
- 10
- Pages
- 1448-1457
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W3199515001
- Cited by
- 320
- References
- 20
- FWCI
- 33.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. https://app.cochat.ai/papers/10.1016/s1470-2045(21)00401-0
- The paper
- Chang, J. Y., Mehran, R. J., Feng, L., Verma, V., Liao, Z., Welsh, J. W., Lin, S. H., O'Reilly, M. S., Jeter, M. D., Balter, P. A., McRae, S. E., Berry, D., Heymach, J. V., Roth, J. A., Antonoff, M., Hofstetter, W., Rajaram, R., Rice, D., Sepesi, B., . . . Wang, X. (2021). Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(21)00401-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.